期刊文献+

骨髓增生异常综合征99例临床分析 被引量:1

Myelodysplastic syndrome:a clinical study of 99 cases.
原文传递
导出
摘要 目的探讨骨髓增生异常综合征(MDS)患者WHO亚型分布、细胞遗传学特点及其与MDS诊断分型、疾病进展和预后的关系。方法回顾性分析2001年1月至2007年12月安徽医科大学附属安徽省立医院血液科收治的99例成人原发MDS患者的染色体核型、WHO分型及预后情况,随访观察并进行相关性研究。结果99例MDS患者难治性贫血(RA)型26例(26.26%);难治性贫血伴环形铁幼粒细胞增多(RAS)型6例(6.06%);难治性贫血伴多系发育异常(RCMD)型23例(23.23%);难治性贫血伴原始细胞增多(RAEB)型44例(44.44%)。按IPSS预后分组,中危Ⅱ和高危组的染色体核型异常检出率明显高于低危和中危Ⅰ组(X^2=17.88,P〈0.01);中危Ⅱ和高危组患者进展为急性白血病的发生率明显高于低危和中危Ⅰ组(X。=40.22,P〈0.01)。按IPSS染色体核型分组,预后好、中、差的患者中位存活期分别为45(95%CI:39~51)、37(95%CI:25~49)和23(95%CI:13~31)个月,Log-rank检验三组总体生存(os)率差异有统计学意义(P=0.010)。结论中国有别于西方国家MDS患者的WHO亚型分布,染色体核型分析是MDS诊断分型及预后评估的重要指标。 Objective To study the WHO classification and cytogenetic characteristics in patients with myelodysplastic syndrome (MDS), and to explore their relationship with diagnosis, progression and prognosis of MDS. Methods Ninty-nine adult patients with primary MDS, admitted to Anhui Provincial Hospital of Anhui Medical University between January 2001 and December 2007, were enrolled in the study. We retrospectively analyzed their chromosomal karyotypes, WHO classifications and prognosis. A follow-up study and correlation analysis were per-formed. Results Among the 99 MDS cases,26(26. 26% ) were diagnosed with RA,6(6. 06% ) with RAS,23 (23.23 % ) RCMD and 44 (44.44%) RAEB. According to IPSS chromosomal prognostic classification, the detection rate of abnormal karyotype was significantly higher in int- Ⅱ/high risk groups than that in low/int-Ⅰ risk groups (X^2 = 17.88, P 〈 0. 01 ) ;the incidence of acute leukemia (AL) was significantly higher in int- Ⅱ/high risk groups than that in low/int-Ⅰrisk groups ( X^2 = 40. 22, P 〈 0. 01 ). According to IPSS chromosomal karyotype classification,the median survival time of patients with good,moderate and poor prognosis were 45 (95% CI:39 - 51 ) , 37 ( 95 % C1:25 - 49 ) and 23 ( 95 % CI : 13 - 31 ) months respectively, with a statistical significance found in overall survival (OS) rates of these three groups (P = 0. 010). Conclusion The features of WHO classification in Chinese patients with primary MDS are different from those in Western countries, and the chromosome karyotype may be of great importance for diagnostic classification and prognostic evaluation of MDS.
出处 《中国实用内科杂志》 CAS CSCD 北大核心 2011年第3期208-210,共3页 Chinese Journal of Practical Internal Medicine
基金 安徽省自然科学基金项目(070413257X) 安徽省卫生厅临床应用项目(2008B018) 安徽省"115"产业造血干细胞移植创新团队资金资助
关键词 骨髓增生异常综合征 染色体 核型分析 WHO分型 myelodysplastie syndrome chromosome karyotype WHO classification
  • 相关文献

参考文献14

  • 1Babicka L, Ransdorfova S, B rezinova J, et al. Analysis of complex chromosomal rearrangements in adult patients with MDS and AML by multicolor FISH [ J ]. Leuk Res,2007,31 ( 1 ) :459 - 471.
  • 2Jaffe ES, Harris NL, Stein H, et al. Pathology and genetics of turnouts of haematopoietic and lymphoid tissues [ M ]. IARC Press, Lyon,2001:61 -75.
  • 3Greenberg P,Cox C, LeBeau MM, et al. International scoring sys- tem for evaluating p rognosis in myelodysp lastic syndromes [ J ]. Blood, 1997,89 (6) :2079 - 2058.
  • 4Germing U, Strupp C, KuendgenA, et al. Prospective validation of the WHO proposals for the classification of myelodysplastic syn- dromes[ J]. Hematologica ,2006,91 (12) :1596 - 1604.
  • 5Howe RB,Porwit-MacDonald A,Wanat R,et al. The WHO classi- fication of MDS does make a difference [ J ]. Blood ,2004,103 (9) : 3265 - 3270.
  • 6Bernasconi P, Klersy C, Boni M. World Health Organization classi- fication in combination with eytogenetic markers improves the prognostic stratification of patients with de novo primary myelodysphstic syndromes [ J ]. Br J Haemato1,2007,137 ( 3 ) : 193 - 205.
  • 7Lee JH, Shin YR, Shin YR. Application of different prognostic scoring systems and comparison of the FAB and WHO classifications in Korean patients with myelodysplastic syndrome [ J ]. Leukemia, 2003,17(2) :305 -313.
  • 8朱平,冯茹,曹香红,董玉君,岑溪南.骨髓增生异常综合征世界卫生组织新分型的临床评价[J].中华血液学杂志,2004,25(6):362-364. 被引量:10
  • 9邱镜滢,赖悦云,柴晔,张艳,师岩,何琦,党辉,陆道培.306例骨髓增生异常综合征染色体核型的研究[J].中国实验血液学杂志,2004,12(4):455-459. 被引量:32
  • 10Sole F, Espinet B, Sanz GF, et al. Incidence, characterization and prognostic significance of chromosome abnormalities in 640 patients with primary myelodysplastie syndromes [ J ]. Br J Haema- tol,2000,108 (2) :346 - 356.

二级参考文献13

  • 1薛永权.伴有8;21染色体易位的骨髓增生异常综合征的新评价[J].国外医学(输血及血液学分册),1997,20(2):105-107. 被引量:1
  • 2Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol, 1982, 51: 189-199.
  • 3Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee Meeting-Airlie House, Virginia, November 1997. J Clin Oncol, 1999,
  • 4Germing U, Gattermann N, Minning H, et al. Problems in the classification of CMML dysplastic versus proliferative type. Leuk Res, 1998, 22: 871-878.
  • 5Nosslinger T, Regina R, Koller E, et al. myelodysplastic syndrome, from French-American-British to World Health Organization: comparison of classifications on 431 unselected patiens from a single institution. Blood, 2001, 98: 2935-2941.
  • 6Matsuda A, jinnail I, Yagasaki F, et al. Refractory anemia with severe dysplasia: clinical significance of morphological featuresin refractory anemia. Leukemia, 1998, 12: 482-485.
  • 7Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood, 1997, 89: 2079-2088.
  • 8Head DR. Revised classification of acute myeloid leukemia. Leukemia, 1996, 10: 1826-1831.
  • 9Vallespi T, Imbert M, Mecucci C, et al. Recent advances in myelodysplastic syndromes: diagnosis, classification, and cytogenetics of myelodysplastic syndromes. Haematologica, 1998, 83: 258-275.
  • 10Germing U, Gattermann N, Strupp C, et al. Validation of the WHO proposals for the classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients. Leuk Res, 2000, 24: 983-992.

共引文献38

同被引文献13

  • 1冯宝章,郝玉书.MDS骨髓细胞癌变的主要机制[J].白血病.淋巴瘤,2006,15(2):148-150. 被引量:7
  • 2Sehlegelberge B, GOhring G, Thol F, et al. Update on cytogenetic and molecular changes in myelddysplastic syndromes(MDS)[J]. Leuk Lymphoma,2011,53(4) :525-536.
  • 3Garcia-Manero G. Myelodysplastic syndromes:2012 update on di- agnosis,risk-stratification, and management [J]. Am J H ematol, 2012,87 (7) : 692-701.
  • 4Della Porta MG, Malcovati L, Strupp C, etal. Risk stratification basedonbothdisease status and extra-hematologic comorbidities in patients with myelodysplasticsyndrome[J]. Haematologica, 2011, 96(3) :441-449.
  • 5Rashidi HH, Xu X, Wang HY, et al. Utility of peripheral blood flowcytometry in differentiating low grade versus high grade my- elodysplasticsyndromes(MDS) and in the evaluation of cytopenias [J] Int J Clin Exp Pathol,2012,5(3) :224-230,.
  • 6Cazzola M,Malcovati L. Prognostic classification and risk assess-ment inmyelodysplastic syndromes[J]. Hematol Oncol Clin North Am,2010,24(2) :459-468.
  • 7Colovic M,Suvajdzic N,Jankovic G,et al. Therapy-related myelo- dysplastic syndrome and acute myeloid leukemia in patients with chronic lymphocytic leukemia treated with fludarabine and cyclo- phosphamide[J]. Biomed Pharmacother, 2011,65 (5) : 319-321.
  • 8邢立娟,杨娜,袁慧云.MRP在急性白血病及MDS患者骨髓涂片中的表达及预后分析[J].中国误诊学杂志,2010,10(19):4603-4603. 被引量:1
  • 9王睿婕,许洪志,黄敏,马春燕,隋潇徽,刘新,张炳昌,李元堂.MDS、AA和AL患者骨髓细胞周期及增殖特征的研究[J].山东大学学报(医学版),2011,49(2):97-101. 被引量:1
  • 10李丽娟,付蓉,王化泉,岳兰竹,刘惠,王琚,王红蕾,阮二宝,瞿文,梁勇,王国锦,王晓明,刘鸿,宋嘉,吴玉红,邢莉民,关晶,邵宗鸿.骨髓增生异常综合征患者骨髓CD34+细胞亚群及其表面造血因子受体的表达[J].中华医学杂志,2011,91(4):234-238. 被引量:6

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部